Global In Silico
Clinical Trials market stood at USD2743.64 million in 2021 and is expected to
grow at a CAGR of 12.28% during the forecast period on account of factors like growing
prevalence of various communicable and non-communicable diseases such as
cancer, diabetes, cardiovascular diseases, neurological disorders, SARS-CoV-2
among others requiring different drugs and medical devices for the treatment.
Before the launch of a drug or medical device it is necessary to conduct
clinical trials. Clinical Trials are generally time consuming, expensive,
harmful for animals, etc. This in turn has led to an increase in demand for
solutions which can help in expediting the rate of clinical trials using
computational tools, software and platforms which can increase the rate of drug
discovery or a new medical device launch, thereby positively influencing the
growth of global In Silico Clinical Trials market.
Rapidly Increasing
Concerns Over Animal Welfare
The growing concerns
related to the harm caused to animals during different types of clinical trials
has created a demand for the development of alternative methods for carrying
out these trials, thereby supporting the market growth. In January 2020, the
US Department of Agriculture had reported that approximately 300,000 animals
were involved in pain causing experimental activities in just one year. In
silico clinical trials offer an effective way of replacing animal anatomies for
conducting various experiments and research & development activities.
Benefits Associated with
In Silico Clinical Trials
Numerous benefits
associated with In Silico Clinical Trials such as their cost effectiveness in
terms of pharmaceutical and therapeutic research, their ability to assess
without any significant delays and additional resources thereby increasing
their scalability, ensuring animal safety, among others are expected to support
the market growth through 2027.
Also, using in silico clinical trials sub
population analysis can be done using computational tools by enriching the
population segment of interest. Same patient population data can be used for
another modality without re-exposing them, leading to a greater scalability.
Sudden Outbreak and
Spread of COVID-19 Pandemic
The sudden outbreak and
spread of COVID-19 pandemic significantly increased the need and demand for In
Silico Clinical Trials since academic & research institutions were shut,
the human participation was reduced due to lockdown and social distancing
norms, among others.
Also, COVID-19 led to the widespread use of platforms such
as Universal Immune System Simulator (UISS) to predict the dynamics of
SARS-CoV-2 and related immune system host response. This platform was also used
to design effective vaccines based on monoclonal antibodies.
